Laura M Kulik
Overview
Explore the profile of Laura M Kulik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
5737
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singal A, Llovet J, Yarchoan M, Mehta N, Heimbach J, Dawson L, et al.
Hepatology
. 2023 May;
78(6):1922-1965.
PMID: 37199193
No abstract available.
2.
Kim H, Choi B, Mouli S, Choi H, Harris K, Kulik L, et al.
Adv Healthc Mater
. 2023 May;
12(26):e2300906.
PMID: 37163283
Herein a practical strategy for augmenting immune activation in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is presented. Pluronic F127 (PF127) is incorporated with Lipiodol (LPD) to achieve safe...
3.
Ganesan P, Kulik L
Clin Liver Dis
. 2022 Nov;
27(1):85-102.
PMID: 36400469
This is a review of current practices and upcoming developments regarding hepatocellular carcinoma (HCC). This includes a contemporary review of the diagnosis, staging, and treatment of HCC. Furthermore, the authors...
4.
Kelley R, Joseph N, Nimeiri H, Hwang J, Kulik L, Ngo Z, et al.
Liver Cancer
. 2021 Dec;
10(6):561-571.
PMID: 34950179
Background: The mammalian target of rapamycin () pathway is upregulated in nearly half of hepatocellular carcinoma (HCC) tumors and is associated with poor prognosis. In preclinical models of HCC, the...
5.
Fix O, Blumberg E, Chang K, Chu J, Chung R, Goacher E, et al.
Hepatology
. 2021 Feb;
74(2):1049-1064.
PMID: 33577086
The aim of this document is to provide a concise scientific review of the currently available COVID-19 vaccines and those in development, including mRNA, adenoviral vectors, and recombinant protein approaches....
6.
Gordon A, Gupta A, Gabr A, Thornburg B, Kulik L, Ganger D, et al.
J Vasc Interv Radiol
. 2020 Dec;
32(2):211-219.
PMID: 33349507
Purpose: To evaluate safety and efficacy of segmental yttrium-90 (Y90) radioembolization for hepatocellular carcinoma (HCC) after transjugular intrahepatic portosystemic shunt (TIPS) placement. The hypothesis was liver sparing segmental Y90 for...
7.
Palmer D, Malagari K, Kulik L
J Hepatol
. 2020 Jan;
72(2):277-287.
PMID: 31954492
Multiple systemic agents have recently been approved in the first- and second-line setting for hepatocellular carcinoma (HCC), increasing the therapeutic options for patients and treating physicians. The randomised controlled trials...
8.
Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M, et al.
Hepatology
. 2018 Apr;
68(2):723-750.
PMID: 29624699
No abstract available.
9.
Hickey R, Kulik L, Nimeiri H, Kalyan A, Kircher S, Desai K, et al.
J Vasc Interv Radiol
. 2017 Sep;
28(11):1487-1494.
PMID: 28912090
Immunotherapy, specifically the use of immune checkpoint inhibitors, offers a new approach to fighting cancer. Although the results of treatment with immune checkpoint inhibition alone have been remarkable for certain...
10.
Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L, et al.
Hepatology
. 2017 Jan;
67(1):358-380.
PMID: 28130846
No abstract available.